Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery […]